Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Successful treatment of diffuse large B-cell lymphoma in a patient with ataxia telangiectasia using rituximab.

Machida S, Tomizawa D, Tamaichi H, Okawa T, Endo A, Imai K, Nagasawa M, Morio T, Mizutani S, Takagi M.

J Pediatr Hematol Oncol. 2013 Aug;35(6):482-5. doi: 10.1097/MPH.0b013e3182804d59.

PMID:
23389503
2.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
3.

Modified chop-chemotherapy plus rituximab for diffuse large b-cell lymphoma complicating ataxia-telangiectasia.

Rossi G, Zecca M, Marchi A, de Stefano P, Sammarchi L, Locatelli F.

Br J Haematol. 2003 Jan;120(2):369-71. No abstract available.

PMID:
12542504
4.

Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma.

Huang YC, Liu CJ, Liu CY, Pai JT, Hong YC, Teng HW, Hsiao LT, Chao TC, Gau JP, Liu JH, Hsu HC, Chiou TJ, Chen PM, Yu YB, Tzeng CH.

Ann Hematol. 2011 Oct;90(10):1145-51. doi: 10.1007/s00277-011-1268-2. Epub 2011 Jun 7.

PMID:
21647583
5.

Herpesviridae viral infections following rituximab combined chemotherapy in patients with diffuse large B-cell lymphoma.

Park LC, Lee HS, Shin SH, Im H, Ye BJ, Song MK, Oh SY, Lee SM, Lee WS, Kim YS.

Acta Haematol. 2011;125(4):230-6. doi: 10.1159/000323421. Epub 2011 Feb 12.

PMID:
21325812
6.

[Diffue large B-cell lymphoma in a child treated by rituximab complicated with chemotherapy].

Chang J, Wang LJ, Wang LZ, Zhang YT, Zhong XD.

Zhongguo Dang Dai Er Ke Za Zhi. 2012 May;14(5):387-8. Chinese. No abstract available.

7.

Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.

Maeshima AM, Taniguchi H, Fukuhara S, Morikawa N, Munakata W, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Tsuda H.

Am J Surg Pathol. 2013 Apr;37(4):563-70. doi: 10.1097/PAS.0b013e3182759008.

PMID:
23426122
8.

Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan.

Tanaka T, Shimada K, Yamamoto K, Hirooka Y, Niwa Y, Sugiura I, Kitamura K, Kosugi H, Kinoshita T, Goto H, Nakamura S.

Ann Hematol. 2012 Mar;91(3):383-90. doi: 10.1007/s00277-011-1306-0. Epub 2011 Aug 6.

PMID:
21822617
9.

Transformed large B-cell lymphoma in rituximab-allergic patient with chronic lymphocytic leukemia after allogeneic stem cell transplant: successful treatment with ofatumumab.

Linden MA, Bachanova V, Sachs Z, Young JA, Singleton TP, Ustun C.

Leuk Lymphoma. 2013 Jan;54(1):174-6. doi: 10.3109/10428194.2012.691484. Epub 2012 May 21. No abstract available.

10.

A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy.

Niitsu N, Tamaru J, Yoshino T, Nakamura N, Nakamura S, Ohshima K, Nakamine H, Okamoto M.

Ann Hematol. 2011 Feb;90(2):185-92. doi: 10.1007/s00277-010-1060-8. Epub 2010 Sep 1.

PMID:
20809421
11.

Rituximab CHOP for successful management of diffuse large B-cell lymphoma of the ovary.

Ahbeddou N, Fetohi M, Khanoussi BE, Errihani H.

Arch Gynecol Obstet. 2011 May;283(5):1173-4. doi: 10.1007/s00404-010-1701-0. Epub 2010 Oct 19. No abstract available.

PMID:
20957380
12.

High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy.

Cardesa-Salzmann TM, Colomo L, Gutierrez G, Chan WC, Weisenburger D, Climent F, González-Barca E, Mercadal S, Arenillas L, Serrano S, Tubbs R, Delabie J, Gascoyne RD, Connors JM, Mate JL, Rimsza L, Braziel R, Rosenwald A, Lenz G, Wright G, Jaffe ES, Staudt L, Jares P, López-Guillermo A, Campo E.

Haematologica. 2011 Jul;96(7):996-1001. doi: 10.3324/haematol.2010.037408. Epub 2011 May 5.

13.

The role of transplantation in diffuse large B-cell lymphoma: the impact of rituximab plus chemotherapy in first-line and relapsed settings.

Rodrigues CA, Patah PA, Novis YA, Hosing C, de Lima M.

Curr Hematol Malig Rep. 2011 Mar;6(1):47-57. doi: 10.1007/s11899-010-0075-5. Review.

PMID:
21190142
14.

Ataxia telangiectasia associated with B-cell lymphoma: the effect of a half-dose of the drugs administered according to the acute lymphoblastic leukemia standard risk protocol.

Yamada Y, Inoue R, Fukao T, Kaneko H, Isogai K, Fukuda S, Shimozawa N, Suzuki Y, Kondo N, Azuma E, Sakurai M.

Pediatr Hematol Oncol. 1998 Sep-Oct;15(5):425-9.

PMID:
9783309
15.

Sustained remission after rituximab-containing chemotherapy for intravascular large B-cell lymphoma.

Shimada K, Kosugi H, Narimatsu H, Shimada S, Suzuki T, Ito M, Kinoshita T, Mori N, Naoe T.

J Clin Exp Hematop. 2008 Apr;48(1):25-8.

16.

[Long-term results of rituximab-based salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma].

Wang XX, Huang HQ, Xia ZJ, Lin XB, Cai QQ, Gao Y, Lin ZX, Lin TY, Jiang WQ.

Nan Fang Yi Ke Da Xue Xue Bao. 2010 Apr;30(4):867-70. Chinese.

17.

Rituximab in treatment of primary gastric diffuse large B-cell lymphoma.

Zhang J, Li G, Yang H, Liu X, Cao J.

Leuk Lymphoma. 2012 Nov;53(11):2175-81. doi: 10.3109/10428194.2012.680451. Epub 2012 Apr 19.

PMID:
22462613
18.

Hepatic non-Hodgkin lymphoma and hepatoblastoma complicating ataxia-telangiectasia.

Cecinati V, Arcamone G, Mattia DD, Santoro N, Martire B.

Immunopharmacol Immunotoxicol. 2012 Feb;34(1):1-3. doi: 10.3109/08923973.2011.567989. Epub 2011 Apr 4.

PMID:
21457128
19.

Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma.

Koivula S, Valo E, Raunio A, Hautaniemi S, Leppä S.

Oncol Rep. 2011 Apr;25(4):1183-90. doi: 10.3892/or.2011.1179. Epub 2011 Feb 10.

PMID:
21318224
20.

Is rituximab one for all ages and each sex?

Habermann TM.

Blood. 2014 Jan 30;123(5):602-3. doi: 10.1182/blood-2013-12-543314.

Supplemental Content

Support Center